46 results about "Chemoradiotherapy" patented technology

The invention discloses an intelligent remote follow-up visit method and system for tumor patients, and relates to the technical field of medical intellectualization, and the method comprises the steps: collecting follow-up visit data through a remote medical terminal, carrying out the processing of the follow-up visit data, obtaining a physical sign index sequence and a symptom feature vector, and generating a dynamic follow-up visit evaluation score through a time sequence prediction model; performing semantic analysis on the electronic medical record data of the patient based on the medical knowledge map, extracting tumor stage classification data, chemoradiotherapy measurement data, weight nutrition indexes and laboratory inspection data, determining a basic risk coefficient, a cumulative dose ratio and a body state score, and generating a baseline follow-up assessment score through a prediction model; and according to the dynamic follow-up evaluation score and the baseline follow-up evaluation score, calculating a comprehensive follow-up grade and generating a next follow-up plan. According to the invention, the accuracy of patient state evaluation is improved, accurate configuration of medical resources is realized, and the quality and efficiency of remote follow-up visit are effectively improved.

The invention discloses a tumor chemoradiotherapy reaction automatic prediction system, and particularly relates to the technical field of medical automation, the tumor chemoradiotherapy reaction automatic prediction system comprises a data acquisition module, a data preprocessing module, a feature extraction and selection module, a model training module, a prediction analysis module, an early warning module and a feedback module; the multi-source data acquisition module comprehensively gathers patient information, the quality is improved through the preprocessing module, a foundation is built for the feature extraction and selection module to accurately screen key features, the data dimension is greatly reduced, and the model training efficiency is remarkably improved; the model training module applies a machine learning algorithm to deeply mine a data complex relationship, so that the prediction is more accurate and reliable; on the basis, the prediction analysis module outputs detailed chemoradiotherapy reaction prediction and provides confidence evaluation to help doctors to make decisions and select; and the early warning module is responsible for predicting, warning abnormity in time and helping doctors to plan intervention in advance.

The invention relates to a multifunctional silica plastid integrating chemotherapy, immunotherapy and gas therapy, and relates to a preparation method of the multifunctional silica plastid and application of the multifunctional silica plastid in tumor diagnosis and treatment. The schematic diagram is as shown in the figure, the membrane components comprise conventional phospholipid and complex lipid, a chemotherapeutic drug doxorubicin (DOX) entrapped on a hydrophilic core and Fe3 (CO) 12 entrapped on a hydrophobic core, and the chemotherapeutic drug can be adjusted according to needs and is suitable for broad-spectrum tumor treatment. The drug-loaded silica plastid can generate part of carbon monoxide in a tumor high-concentration hydrogen peroxide (H2O2) environment and release internally-loaded chemotherapeutic drugs. Under the action of ultrasound (US), the multifunctional silicon plastid can realize fixed-point release of chemotherapeutic drugs DOX and carbon monoxide at a tumor site, the enrichment and uptake of the drugs at the tumor site are greatly improved, in addition, the system is combined with the alphaPD-L1 antibody, the immunosuppressive PD-L1 / PD-1 axis can be blocked, T cells are recruited to attack tumors, meanwhile, the immunosuppressive regulatory T cells (Tregs) are reduced, and the tumor treatment effect is improved. The tumor inhibition can be enhanced; the pulmonary metastasis can be obviously reduced.

The invention discloses a novel nucleic acid delivery system based on phosphatidylmitoxantrone as well as a preparation method and application of the novel nucleic acid delivery system based on phosphatidylmitoxantrone, and phosphatidylmitoxantrone (PMA) is used as a novel cationic lipid to construct a novel lipidosome nano nucleic acid delivery system by utilizing the enzymatic response release property and ionizable cationic phospholipid characteristics of phosphatidylmitoxantrone (PMA). PMA not only can be used as a novel cationic lipid entrapped nucleic acid, but also can be used as an auxiliary lipid component to promote nucleic acid delivery, so that the synergistic anti-tumor effect of nucleic acid and mitoxantrone is realized. The system can respond to high expression of phospholipase D (PLD) in tumor tissues, promote hydrolysis of PMA and release chemotherapeutic drug mitoxantrone, dual functions of nucleic acid delivery and drug release are achieved, the purpose of double-target inhibition of tumor growth is achieved, and a new strategy is provided for cancer treatment.

The invention relates to the technical field of medicines, in particular to a tumor chemotherapy medicine liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: taking an ethanol solution of lipid molecules as an organic phase, taking an aqueous solution containing transition metal acetate as a water phase, mixing the organic phase and the water phase in a microchannel, and collecting an outflowing transition metal acetate nano-liposome solution; carrying out medium exchange on the nano-liposome, and removing the transition metal acetate in the external water phase to obtain the liposome of which only the internal water phase contains the transition metal acetate; and mixing the liposome with an anthracycline chemotherapeutic drug, adjusting the pH value to near neutral-alkalescence, and heating to promote remote loading of the liposome on drug molecules, so as to obtain the chemotherapeutic drug-loaded nano-liposome. The liposome has a tumor acidic microenvironment slow release function, can specifically target tumor cells by using the targeting component, improves delivery and release of chemotherapy drugs into tumors, and can be used as a tumor chemotherapy and chemoradiotherapy combined treatment nano-drug.

The invention discloses an ultrasonic activation type carrier-free nano-drug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano-drug is formed by self-assembly of a sound-sensitive agent and a chemotherapy prodrug, the sound-sensitive agent is an organic small molecule capable of generating ROS through ultrasonic irradiation, and the chemotherapy prodrug is an ROS response type SN38 prodrug. Only after the carrier-free nano-drug provided by the invention is subjected to ultrasonic irradiation, the sound-sensitive agent can generate active oxygen, further activate the chemotherapeutic prodrug and release the active substance of the chemotherapeutic drug to induce tumor cell apoptosis, the tumor treatment effect is improved in an ultrasonic triggering manner, and toxic and side effects caused by non-specific distribution of the chemotherapeutic drug are avoided. The preparation method disclosed by the invention is simple and mild in reaction condition, and has great potential in the fields of preparation and application of tumor drugs.

The invention discloses a special medical application formula and a preparation method of a selenium-rich ginseng medicinal and edible herbal liquid, and belongs to the technical field of health foods and special medical foods. The formula is prepared from a selenium-enriched ginseng extract, Chinese yam powder, a poria cocos extract, a gordon euryale seed extract, a Chinese date extract, a longan aril extract and auxiliary materials through scientific compatibility, and has the effects of tonifying spleen and kidney, reinforcing qi and nourishing blood aiming at the pathogenesis of spleen and kidney deficiency and deficiency of qi and blood. According to the preparation method, a gradient process combining ultrasonic-assisted ethanol extraction and enzymolysis water extraction is adopted, and active ingredients such as organic selenium, ginseng rare saponin, jujube cAMP and longan polysaccharide are efficiently extracted and reserved. Experiments show that the herbal liquid has a remarkable synergistic effect in the aspects of improving immunity, improving hematopoietic function and resisting fatigue, and is suitable for nutrition support and function conditioning of tumor chemoradiotherapy patients and postoperative weak people.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.

The invention relates to the technical field of gene engineering, in particular to SgRNA for targeted knockout of an MINOS1 gene and application of the SgRNA. According to the invention, a CRISPR / Cas9 gene knockout technology is adopted, a LentiCRISPR-V2 vector is constructed by using a CRISPR / Cas9 system, the LentiCRISPR-V2 vector is co-transferred into a porcine small intestine epithelial cell to obtain a positive cell clone, an MINOS1 gene in the positive cell clone is not expressed, the cell death rate under a hypoxia condition can be obviously reduced, and the positive cell clone has hypoxia tolerance. By regulating and controlling MINOS1 expression, the adaptive capacity of an organism to a low-oxygen environment can be enhanced, and a new thought is provided for preventing and relieving altitude stress and improving physiological tolerance in an extreme environment; besides, the hypoxia characteristic of the tumor microenvironment is a key factor causing chemoradiotherapy drug resistance, and the MINOS1 knockout related strategy can reverse the hypoxia tolerance phenotype of tumor cells, so that the sensitivity of the tumor cells to treatment is enhanced, and an innovative direction is provided for overcoming tumor drug resistance.

The invention discloses a traditional Chinese medicine composition for reinforcing qi and nourishing blood and a detection method thereof. The traditional Chinese medicine composition is prepared from ginseng, astragalus membranaceus, Chinese yam, lily, colla corii asini, roasted rhizoma atractylodis macrocephalae, pulp of dogwood fruit, ligustrum lucidum, schisandra chinensis, pericarpium citri reticulatae, rhizoma anemarrhenae, cornu cervi pantotrichum and lycium barbarum. According to the theory of traditional Chinese medicine, the prescription is screened by adopting the theory of treatment based on syndrome differentiation, and the medicines are scientifically and reasonably matched, have the effects of reinforcing qi, nourishing blood, consolidating the body resistance and strengthening the body resistance, and are used for treating shortness of breath, palpitation, lusterless complexion, weakness and weakness caused by deficiency of qi and blood. In addition, the traditional Chinese medicine composition can improve the body immunity of patients with deficiency of qi and blood, and can also be used for reducing adverse reactions such as myelosuppression and thrombocytopenia caused by radiotherapy and chemotherapy. Content determination is carried out through TLC identification and HPLC, and a scientific basis is provided for guaranteeing the clinical quality and effectiveness of reinforcing qi, nourishing blood and strengthening body resistance.

Embodiments of the disclosure include particular amyloglucosidase (AMG) compositions formulated as a nutriceutical or medicinal food, for example. The AMG compositions are formulated at a specific dosage and / or are lacking in one or more toxins or have substantially reduced levels of toxin, such as deoxynivalenol (vomit toxin). The AMG compositions are provided to individuals in need thereof, such as an individual with or at risk for congenital sucrase isomaltase syndrome, functional bowel disorders, small bowel bacterial overgrowth, protein-calorie malnutrition (marasmus), radiochemotherapy-induced mucositis and / or short-gut syndrome.

The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

The invention discloses a traditional Chinese medicine composition for treating middle and advanced stage tumors. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-11 parts of ganoderma lucidum slices, 1-3 parts of radix angelicae sinensis, 1-3 parts of cordyceps militaris, 5-7 parts of poria cocos, 1-3 parts of fructus lycii, 2-4 parts of radix astragali, 5-7 parts of polyporus umbellatus, 3-5 parts of ginseng slices and 3-5 parts of exocarpium citri grandis. The traditional Chinese medicine composition has the effects of benefiting qi and nourishing blood, tonifying kidney and spleen, and supporting healthy energy. The traditional Chinese medicine is used for treating qi and blood deficiency syndromes caused by middle and advanced tumors, wherein the syndromes comprise mental exhaustion, limb weakness, body emaciation, pale complexion, inappetence and the like. The traditional Chinese medicine composition can also be used for relieving toxic and side effects after radiotherapy and chemotherapy and early treatment of cancers. The invention further discloses a method for preparing the traditional Chinese medicine composition, the dosage form advantage is remarkable, the preparation process is stable and controllable, and the method is suitable for industrial production.

The invention belongs to the field of biological medicine, and relates to degradable monodisperse embolism microspheres loaded with radionuclides and chemotherapeutic drugs and a preparation method of the degradable monodisperse embolism microspheres. The embolism microspheres are composed of degradable polymer microspheres with negative charges, radionuclides and chemotherapeutic drugs with positive charges. Radionuclides are connected to the degradable polymer microspheres through chemical bonds, and chemotherapeutic drugs with positive charges are loaded on the degradable polymer microspheres through electrostatic adsorption; the embolism microsphere is spherical, the particle size is 20-100 microns, and the variable coefficient of the particle size does not exceed 10%; the base material of the degradable polymer microspheres is formed by photo-initiation polymerization of two different photopolymerization macromolecules. The embolism microsphere provided by the invention can realize in-vivo chemoradiotherapy synergistic treatment, in-vivo development and in-vivo degradability, and has excellent monodispersity at the same time.

The invention relates to the field of biomedical application, in particular to a group of cfDNA methylation markers related to muscular tension after glioblastoma operation and chemoradiotherapy treatment as well as a prediction model and application of the cfDNA methylation markers. The invention provides a novel cfDNA methylation marker, and the novel cfDNA methylation marker has innovativeness and specificity. Noninvasive detection is realized, and clinical application and dynamic monitoring are facilitated. An accurate prediction model and a standardization tool are developed, and standardization and individualization of treatment effect monitoring are promoted. The method has wide application value and can be used for treatment effect evaluation, prognosis prediction and treatment strategy optimization. A novel molecular mechanism is disclosed, and scientific basis and reference are provided for tumor research. Due to the advantages, the invention has important application prospect and scientific value in the fields of clinical diagnosis and treatment and scientific research of glioblastoma.

Methods for treating solid tumors with anti-PD-L1 and anti-CTLA-4 antibodies concurrently with chemoradiotherapy (cCRT) are disclosed.

The invention discloses an acute pneumonia inhibitory ginsenoside Rb1 monomer and application thereof, and relates to the technical field of biological medicines. The ginsenoside Rb1 is screened from a natural product library through a high-throughput screening method, and the ginsenoside Rb1 plays a role in inhibiting expression of inflammatory factors mediated by a menin / SETD2 compound. The monomer can be applied to preparation of anti-inflammatory drugs, anti-tumor drugs, radiotherapy and chemotherapy adjuvant therapy drugs, anti-cytokine storm syndrome (CSS) drugs, lung protection drugs and the like. The compound is applied to drugs for treating acute pneumonia related to inflammatory factor over-activation induced by microbial infection and physical and chemical factors, including inhibition of inflammatory factor expression, reduction of lung tissue inflammatory cell infiltration and pulmonary alveolar protein deposition and the like. The monomer can also effectively inhibit release of lung epithelial cell inflammatory factors induced by ionizing radiation and chemotherapeutic drug exposure. The compound has the advantages of definite action target, high efficiency, specificity, remarkable curative effect, low toxicity and the like.

The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

The present invention discloses a method for predicting the risk of esophageal fistula based on clinical data and imaging omics features, which relates to the field of medical artificial intelligence technology. The present invention combines deep learning with traditional imaging omics methods, extracts rich imaging omics features through multiple image processing technologies, and ensures the generalization ability and robustness of the model through a multi-stage feature selection strategy. It develops multiple prediction models based on different feature combinations, including clinical feature models, manually produced imaging omics models, deep learning imaging omics models, clinical-deep learning imaging omics models, and clinical-manually produced imaging omics models. Through cross-validation and model optimization, the efficiency of each model in clinical prediction is ensured, the performance of the models is comprehensively compared, and the prediction model most suitable for clinical application is selected to further improve the accuracy and reliability of the prediction. The present invention improves the accuracy of esophageal fistula risk prediction in esophageal cancer patients after radiotherapy or chemoradiotherapy, provides a strong basis for treatment decision-making for esophageal cancer patients, and has broad clinical application prospects.

The invention discloses an esophageal squamous carcinoma immunotherapy prediction method and device, equipment and a medium. The method comprises the following steps: acquiring CT image data of a case; the CT image data is image data before neoadjuvant immunotherapy combined with radiotherapy and chemotherapy; the case is an esophageal squamous cell carcinoma patient to receive neoadjuvant immunotherapy combined radiotherapy and chemotherapy; obtaining a region of interest after the CT image data is sketched; extracting radiomics characteristics of the region of interest; inputting the radiomics characteristics into the target esophageal squamous cell carcinoma immunotherapy prediction model to obtain a prediction result; the prediction result is used for indicating the prognosis state of the case in receiving the neoadjuvant immunotherapy combined radiotherapy and chemotherapy. Therefore, in combination with a non-invasive imaging analysis means of imaging omics and through the pre-constructed target esophageal squamous cell carcinoma immunotherapy prediction model, whether the patient obtains complete pathological relief through combination of new auxiliary immunotherapy and chemoradiotherapy is predicted, so that immunotherapy is guided, and the survival rate of the esophageal squamous cell carcinoma patient is increased.

The present invention belongs to the technical field of pharmaceutical preparations, and discloses a Fagopyrum dibotrys solution preparation for aerosol inhalation, its preparation method and application. The present invention provides a Fagopyrum dibotrys solution preparation for aerosol inhalation, including: the effective components of Fagopyrum dibotrys are obtained by extracting Fagopyrum dibotrys with an aqueous ethanol solution, subjecting it to alcohol precipitation, and then separating and purifying the obtained solution by resin adsorption. The present invention also provides a preparation method of the Fagopyrum dibotrys solution preparation for aerosol inhalation. The Fagopyrum dibotrys solution preparation for aerosol inhalation provided by the present invention is used in the application of drugs having the effects of enhancing the efficacy and reducing the toxicity in the radiotherapy and chemotherapy of lung tumors. This preparation is administered to patients by aerosol inhalation, directly delivering the drug to the lungs. It not only uses a small dose, has a quick onset of action, but also is safe, effective, has a high bioavailability, and has no other toxic side effects.

The application provides a nano regulator and a preparation method and application thereof. Specifically, water regulation drugs and chemotherapy drugs are co-delivered through metal organic framework nanoparticles or metal polyphenol nanoparticles, the tumor-targeted enrichment and microenvironment-responsive release characteristics of the nano regulator are utilized to release the chemotherapy drugs at the tumor site after cryoablation. The nano regulator can be used for cryoablation sensitization and chemotherapy synergistic treatment, thereby effectively improving the tumor inhibition effect.

The invention is applicable to the technical field of pharmaceutical preparations, and provides bionic nanoparticles MDI-CCM as well as a preparation method and application thereof. Bionic nanoparticles MDI-CCM are constructed, based on mesoporous silica nanoparticles loaded with doxorubicin (DOX) and indocyanine green (ICG), acid-sensitive controlled-release column [5] arene (WP [5] as a nano valve) is constructed on the surface, a tumor cell membrane is coated to realize homologous targeting of tumor cells, the nano valve triggers controllable release of drugs in a tumor microenvironment, and the drug delivery effect is improved. DOX chemotherapy and ICG near-infrared laser photo-thermal effect form synergy, and the treatment effect on 4T1 breast cancer tumors is enhanced. Experimental results show that the MDI-CCM can significantly inhibit tumor growth, has the characteristics of low toxicity, high drug loading capacity, active targeting and intelligent controlled release, can be applied to homologous targeting and chemotherapy-photothermal synergistic treatment of cancers such as breast cancer, and provides new insight and basis for related treatment.

The present disclosure relates to methods, combinations and uses for the treatment of cervical cancer using an anti-PD-L1 binding protein or an anti-PD-1 binding protein and chemoradiotherapy.

The invention relates to the technical field of radiotherapy and chemotherapy sensitizers, in particular to application of a preparation with an EMILIN1 gene inhibition effect in preparation of a radiotherapy and chemotherapy sensitizer. Based on deep research on colorectal cancer tumor microenvironment and tumor-related fibroblasts, the invention finds that the expression of EMILIN-1 in radiotherapy and chemotherapy resistant patients is remarkably up-regulated. By designing the siRNA to specifically inhibit the expression of the EMILIN1 gene, the chemoradiotherapy sensitivity of the colorectal cancer can be effectively improved. The invention provides various application forms such as cholesterol-modified siRNA and tumor-associated fibroblasts transfected with siRNA, and the sensitivity of colorectal cancer cells to radioactive rays and chemotherapeutic drugs is remarkably improved. According to the technical scheme, the technical problem that in the prior art, a means capable of effectively inhibiting the chemoradiotherapy resistance phenomenon of the colorectal cancer cells is lacked can be solved, multiple choices are provided for clinical transformation, and good development and application prospects are achieved.

The invention discloses application of an MARCO inhibitor combined with radiotherapy and chemotherapy in treatment of glioma. The invention creatively discovers that the MARCO inhibitor, the radiotherapy and the chemotherapy or the combined use of the MARCO inhibitor, the radiotherapy, the chemotherapy and the PD-1 inhibitor has a remarkable synergistic effect on the glioma for the first time, and the treatment effect of the combined medication mode on the glioma is remarkably superior to that of a single MARCO inhibitor or a chemoradiotherapy strategy. The advantage in treatment of glioma is obvious. The invention provides an effective drug combination strategy for treatment of glioma, and has a good clinical application prospect and important transformation significance in the technical field of research and development of glioma treatment drugs.

The invention discloses an iridium complex, a preparation method thereof and application of the iridium complex in chemoradiotherapy synergistic treatment. In the prior art, the design of systematic'combination of chemoradiotherapy and active targeting 'of iridium complexes and the report of clear mechanism-level evidence (such as gamma-H2AX, cell cycle and the like) are still limited. The invention discloses an iridium complex nano-drug and an application thereof in breast cancer chemoradiotherapy synergistic treatment, the iridium complex nano-drug has high atomic number elements and a targeting molecular nano-material, can enhance radiation energy deposition and enrich tumor tissues, and is a direction for improving radiotherapy sensitivity; the iridium complex has the characteristics of AIE performance, mitochondrial targeting, ROS production and the like, and is expected to be used as a chemotherapy sensitizer and an imaging probe.

The invention relates to a lactylation modified XLF protein, a preparation for inhibiting XLF lactylation and application. The research finds that the function of the XLF in the NHEJ process is adjusted by promoting the interaction between the XLF and Ku80 through protein lactylation. Under the catalysis of GCN5 (lysine acetyltransferase 2A, KAT2A), XLF is lactylated, so that the efficiency of NHEJ is improved, and colorectal cancer (CRC) cells are caused to generate chemotherapy resistance. In addition, inhibition of XLF lactic acidification can increase sensitivity of CRC cells to chemoradiotherapy. A polypeptide is also obtained through design and screening, the polypeptide can specifically inhibit the lactylation of XLF at K288, a synergistic effect is generated on CRC when the polypeptide is combined with 5-FU, and the polypeptide can promote the chemosensitivity of colorectal cancer.

The invention discloses a nutrition nursing intervention system and method for tumor radiotherapy and chemotherapy patients, and belongs to the field of nutrition nursing intervention. Patient data, patient basic information and treatment schemes are obtained, a dynamic knowledge base is constructed, a nutrient element intake gap model is constructed, and a nutrition element intake gap model is constructed; the method comprises the following steps: importing recommended daily intake and actual daily intake of nutrient elements of a patient into a nutrient element intake gap model to evaluate a nutrient gap, constructing a drug metabolism and organ tolerance model, and importing radiotherapy and chemotherapy drug parameters into the drug metabolism and organ tolerance model to evaluate a drug metabolism condition and an organ tolerance dose. The method comprises the following steps: constructing a nutrition risk assessment model, and introducing a nutrient element relative gap vector, a drug metabolism amount, an organ tolerance dose and a tumor stage of a patient into the nutrition risk assessment model to assess the nutrition risk of the patient, so that the nutrition risk of the patient is assessed by integrating the nutrition intake condition, the drug metabolism process and the organ tolerance of the patient; and performing nutrition nursing intervention on the patient.